Education
About Us
Working with TipRanks
Follow Us
Profound Medical (TSE:PRN)
TSX:PRN
PRN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$5.58 - C$15.75
Previous CloseN/A
Volume2.80K
Average Volume (3M)7.62K
Market Cap
C$202.77M
Enterprise ValueC$206.72M
Total Cash (Recent Filing)$54.91M
Total Debt (Recent Filing)$5.12M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 08, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding30,039,808
10 Day Avg. Volume5,937
30 Day Avg. Volume7,623
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.88
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.38
Enterprise Value/Ebitda-6.34
Forecast
1Y Price Target
C$20.23Price Target Upside199.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Profound Medical News
PremiumCompany Announcements
Profound Medical to Announce Q1 2025 Financial Results
PremiumCompany Announcements
Profound Medical Unveils Agenda for AUA 2025 Investor Event
PremiumCompany Announcements
Profound Medical to Host Investor Event at AUA 2025PremiumCompany Announcements
Profound Medical’s Earnings Call: Optimism Amid Growth
PremiumCompany Announcements
Profound Medical to Announce 2024 Financial Results and Host Conference Call
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsProfound’s CAPTAIN trial is expected to provide the first ever Level 1 clinical trial data in prostate cancer, which could highlight the superiority of TULSA over traditional treatments.
Growth StrategyProfound reported Q4 results mostly in line with expectations and guided to 70%-75% growth this year, with the opportunity to reach triple-digit growth rates next year and beyond.
Market PositionTULSA is now the only ablative technology of any type or indication to reach Ambulatory Payment Classification (APC) level 7, while all other prostate cancer treatment modalities are at level 6.
Bears Say
Equity DilutionThe target price for the stock mechanically reduces to $17.00 due to equity dilution.
Market RisksThe issuance of new shares was at a 7% discount to the previous closing price, but shares were trading above this issue price, indicating investor confidence.
Operational ChallengesThe company's goal of 75 TULSA installs by year-end seems unlikely to be achieved.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.59% Insiders
1.34%
Mutual Funds
36.15% Other Institutional Investors
43.86% Public Companies and
Individual Investors
PRN FAQ
What was Profound Medical’s price range in the past 12 months?
Profound Medical lowest stock price was C$5.58 and its highest was C$15.75 in the past 12 months.
What is Profound Medical’s market cap?
Profound Medical’s market cap is C$202.77M.
When is Profound Medical’s upcoming earnings report date?
Profound Medical’s upcoming earnings report date is May 08, 2025 which is in 21 days.
How were Profound Medical’s earnings last quarter?
Profound Medical released its earnings results on Mar 06, 2025. The company reported -C$0.279 earnings per share for the quarter, beating the consensus estimate of -C$0.449 by C$0.17.
Is Profound Medical overvalued?
According to Wall Street analysts Profound Medical’s price is currently Undervalued.
Does Profound Medical pay dividends?
Profound Medical does not currently pay dividends.
What is Profound Medical’s EPS estimate?
Profound Medical’s EPS estimate is -0.39.
How many shares outstanding does Profound Medical have?
Profound Medical has 30,039,808 shares outstanding.
What happened to Profound Medical’s price movement after its last earnings report?
Profound Medical reported an EPS of -C$0.279 in its last earnings report, beating expectations of -C$0.449. Following the earnings report the stock price went down -4.159%.
Which hedge fund is a major shareholder of Profound Medical?
Currently, no hedge funds are holding shares in TSE:PRN
---
Profound Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$20.23 (199.70% Upside)
C$20.23 (199.70% Upside)
Blogger Sentiment
Bullish
TSE:PRN Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth C$139.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.16%
12-Months-Change
Fundamentals
Return on Equity
-59.43%
Trailing 12-Months
Asset Growth
207.58%
Trailing 12-Months
Company Description
Profound Medical
Profound Medical (PRN) is a Canadian-based medical technology company that operates within the healthcare sector, focusing on the development and commercialization of innovative therapeutic technologies. The company's core product, TULSA-PRO, is a minimally invasive technology that combines real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control for the precise ablation of prostate tissue.
---
PRN Stock 12 Month Forecast
Average Price Target
C$20.23
▲(199.70% Upside)
Technical Analysis
Best Analysts Covering PRN
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-21.10%
reiterated a buy rating last month
Copying Ben Haynor's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -21.10% per trade.
---